GSMA
18.9.2018 12:43:07 CEST | Business Wire | Press release
Europe’s mobile ecosystem is forecast to account for more than 4 per cent of the region’s GDP by 2022, but the right regulatory action must be taken to position Europe as a global 5G leader and establish a genuine EU Digital Single Market, according to a new report published by the GSMA today. The latest regional edition of the GSMA’s flagship Mobile Economy series was released today at the GSMA Mobile 360 – Europe conference, where senior representatives from the mobile industry and regulatory bodies are convening to debate the future of telecoms in Europe.
“5G networks in Europe are expected to provide coverage to almost three-quarters of the region’s population by 2025 and Europe is set to become the world’s third-largest 5G market behind Asia Pacific and North America by this point,” commented Mats Granryd, Director General of the GSMA. “However, success in the 5G era will rest on the ability of governments to implement forward-looking regulatory frameworks that encourage sustainable investment, drive innovation and protect consumers.”
Mobile a Driver of Economic Growth in Europe
In 2017, mobile technologies and services generated 3.3 per cent of GDP1 in Europe, a contribution that amounted to EUR550 billion of economic value added. This contribution is expected to increase to EUR720 billion (4.1 per cent of GDP) by 2022. Europe’s mobile ecosystem also supported 2.5 million jobs in the region in 2017 and made a public funding contribution of EUR100 billion – mainly in the form of general taxation, including VAT, corporate taxes and employment taxes.
Reforms to Drive Digital Evolution
For Europe to realise the full potential of 5G, it needs to create a more supportive policy environment that positions it as a preferred location for investment. Regulation should seek to:
- Encourage a strong pro-investment environment that will allow the mobile industry to make investments that will ultimately benefit consumers;
- Support a policy of ‘same service, same rules’ that would lead to more competition, innovation and higher consumer welfare;
- Provide timely access to harmonised spectrum in the right frequencies, at the right time, and under the right long-term conditions for operators to invest in future networks and services; and
- Enable European operators to harness the full potential of data to innovate and compete globally while protecting the privacy and confidentiality of consumers
Europe Prepares to Move to 5G
Europe is the most highly penetrated regional mobile market in the world. According to today’s report, there were 465 million unique mobile subscribers2 in Europe at the end of 2017, representing 85 per cent of the population. This is forecast to grow to 481 million – 88 per cent of the population – by 2025.
Although there is still headroom for 4G growth in many markets, the first 5G launches by European mobile operators are anticipated by the end of the decade. By 2025, it is forecast that 5G will account for around 200 million connections, corresponding to a 29 per cent share of total connections in Europe.3
“Momentum is now building in Europe as we enter the 5G era, as mobile operators conduct trials and prepare to ramp up 5G investments over the coming years,” added Granryd. “Meanwhile, in light of ongoing financial and competitive pressures, Europe’s operators are looking beyond their core telco business in order to explore and unlock new revenue streams in both consumer and enterprise markets across a range of verticals.”
The new report ‘The Mobile Economy: Europe 2018’ is authored by GSMA Intelligence, the research arm of the GSMA. To access the full report and related infographics, please visit: www.gsma.com/mobileeconomy/europe/
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators with over 350 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA .
1 GDP contribution includes direct mobile ecosystem contribution (0.9%); indirect contribution (0.5%); and productivity improvements (1.9%)
2 A unique mobile subscriber represents an individual that can account for multiple SIM connections
3 Excluding licenced cellular IoT connections
View source version on businesswire.com: https://www.businesswire.com/news/home/20180918005468/en/
Contact:
For the GSMA Beau Bass +44 79 7662 4962 beau.bass@webershandwick.com or Olivier Lechien +32 479 99 01 63 olechien@gsma.com or GSMA Press Office pressoffice@gsma.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
